Status:
COMPLETED
Absolute Bioavailability Of Bosutinib
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is an open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study in healthy subjects.
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects (of non-childbearing potential).
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, accept placement of indwelling catheter for infusion and other study procedures.
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies).
- A positive urine drug screen for cocaine, tetrahydrocannabinol (THC), opiates/opioids, benzodiazepines and amphetamines.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT02192294
Start Date
August 1 2014
End Date
October 1 2014
Last Update
October 31 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Clinical
Ruddington Fields, Nottingham, United Kingdom, NG11 6JS